Towards The Eradication Of Hepatitis B In Taiwan
A Discussion Paper
Dr. Suzanne Wait

Table of Contents 


Executive Summary
I.         Introduction: Hepatitis B in Taiwan

II.        What is hepatitis B?
Who is at risk of becoming infected?
Natural history
A silent disease
Liver cancer
A significant economic burden

III.       Managing hepatitis B disease: prevention, screening and treatment
Vaccination: the most effective prevention
Targeted prevention of high-risk groups

IV.      Challenges to containing hepatitis B in Taiwan
A huge success story...
...Yet challenges remain:
1.    Need for greater awareness and education
2.    Need to ensure continued success of the vaccination programme
3.    Need to improve standards of care for the management of hepatitis B
4.    Need to overcome geographic and social inequities in access to care

V.       The way forward 

VI.      References


Viral hepatitides have long been important public health problems in humans. The etiologic agents were not identified, until around 1965 when Baruch S. Blumberg first found the relationship of Australia antigen and serum hepatitis. Further characterizations revealed the antigen to be the surface antigen of the hepatitis B virus. This epoch-making observation launched a new era in the diagnosis, prevention and treatment of hepatitis B. In about 15-20 years, the natural history of hepatitis B virus infection was elucidated, and more importantly, an effective vaccine against the infection became available. In the meantime, the routes of transmission were also made clear, rendering interruption of the transmission more specific and effective. The hepatitis B vaccine together with the effective means of interrupting the transmission routes contributed greatly to the control of hepatitis B virus infection. However, these measures can do very little to those who have already been chronically infected. Fortunately, specific therapies against chronic hepatitis B have started to appear about 10-15 years before and the treatments improved substantially in the last few years. Although far from perfect, now we do have some effective means to treat those who are chronically infected.
In Taiwan, acute and chronic liver diseases have been known to be rampant in as early as the beginning of the last century. Studies around 1975 showed an extreme high prevalence of chronic hepatitis B infection in the general population (15%-20%), and 80%-90% of the chronic liver diseases as well as hepatocellular carcinoma were caused by chronic infection with the hepatitis B virus. This important health problem, repeatedly addressed by the academia in Taiwan, finally caught the attention of the Government in the late 1970s, and a government-sponsored control program was finalized in 1981. Accordingly, a mass vaccination program against hepatitis B, primarily aiming at immunizing newborn infants, was launched on July 1, 1984. Twenty years after implementation of the program, the hepatitis B carrier rate in children covered by the program decreased 85%, from ~15% to <1%. Most importantly, the deadly sequela of hepatocellular carcinoma in the vaccinees was also found to decrease in parallel . This is the first time in history that a human cancer is prevented by vaccination. Despite the success, there are still some who were born after implementation of the program but were not prevented from chronic hepatitis B infection and hepatocellular carcinoma. Non-compliance to vaccination schedule, breakthrough infection and intrauterine infection are the causes of the failure.
At present, we have effective measures in immunizing the susceptibles, interrupting the routes of transmission and treating the chronically infected people. The time of considering elimination or even eradication of hepatitis B virus infection has come. This is especially true for countries where hepatitis B infection is not endemic. Nevertheless, with the admirable results achieved in the past, Taiwan should also start to think about elimination/eradication of hepatitis B in the country, even though it will certainly be much more difficult than in the non-endemic countries.
Dr Suzanne Wait has spent substantial efforts and time in exploring the possibility of eliminating/eradicating hepatitis B in Taiwan. She reviewed the epidemiology of hepatitis B, and analyzed the problems that remain to be tackled in Taiwan. With this essay as an important reference, I hope that Taiwan can take further steps towards the elimination or eradication of hepatitis B.

Ding-Shinn Chen, M. D.
Distinguished Chair Professor
Division of Gastroenterology and Hepatology
Department of Internal Medicine
National Taiwan University College of Medicine

Staff Physician
Hepatitis Research Center
National Taiwan University Hospital
7 Chung-Shan South Road

April, 2010 Taipei 10002, TAIWAN

Download full paper:

FaLang translation system by Faboba


>> CEVHAP Strategy 2017-2021



NOhep is a global, grassroots movement aimed at bringing all stakeholders together to eliminate viral hepatitis by 2030. It has been developed to create global awareness of the disease, similar to the red ribbon for HIV/AIDS, and was launched in 2016. NOhep firmly positions itself at the forefront of the elimination conversation, showcasing exemplary leadership, fostering on-the-ground innovative solutions and taking action to support the policy changes needed to eliminate this cancer-causing illness by 2030. Being a part of NOhep means being part of the solution. (To find out more about the development of this exciting initiative, watch this short video:

Viral Hepatitis
  Globally, 2 billion people have been
infected with hepatitis B virus, with an
estimated 600,000 dying each year . . .
  The number of people with chronic
hepatitis C and more advanced liver
disease or cirrhosis, is projected to
increase by 38% between 2006 and 2015
unless the number of people being
treated increases substantially.
  There is no vaccine for hepatitis C but
approximately 80% of patients who are
able to complete recommended
treatment, are cured . . .
Why hepatitis policy matters - the story of Baltazar Lucas  
Video What are the dangers of viral #hepatitis? Hear what #CEVHAP Chair Prof Ding-Shinn Chen had to say to the Wall Street Journal.
A Message from DS Chen
Chairman, CEVHAP


Connect with usconnect with CEVHAP